828 related articles for article (PubMed ID: 24676847)
1. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
2. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
5. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
[TBL] [Abstract][Full Text] [Related]
6. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
McClung MR; Lewiecki EM; Geller ML; Bolognese MA; Peacock M; Weinstein RL; Ding B; Rockabrand E; Wagman RB; Miller PD
Osteoporos Int; 2013 Jan; 24(1):227-35. PubMed ID: 22776860
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
8. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
9. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.
Recknor C; Czerwinski E; Bone HG; Bonnick SL; Binkley N; Palacios S; Moffett A; Siddhanti S; Ferreira I; Ghelani P; Wagman RB; Hall JW; Bolognese MA; Benhamou CL
Obstet Gynecol; 2013 Jun; 121(6):1291-1299. PubMed ID: 23812464
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD
Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
[TBL] [Abstract][Full Text] [Related]
11. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
[TBL] [Abstract][Full Text] [Related]
13. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
14. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
15. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
[TBL] [Abstract][Full Text] [Related]
16. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
17. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
18. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
20. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
McClung MR; Balske A; Burgio DE; Wenderoth D; Recker RR
Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
